FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

Telix Resubmits NDA for Brain Cancer Imaging Agent Pixclara

Telix Pharmaceuticals refiles an NDA seeking approval of its investigational PET imaging agent Pixclara (TLX101-Px, also known as 18F-FET) for evaluat...

latest-news-card-1
Human Drugs

FDA Flags Sterility, Contamination Control Issues at India Plant

FDA inspectors cite multiple manufacturing and quality control deficiencies at a Gland Chemicals Private Limited in Chennai, India, manufacturing faci...

latest-news-card-1
FDA General

FDA Updates Internal Procedures for Handling Supplements

FDA updates an internal policy document outlining how CBER staff process supplements to approved drug and biologic applications.

latest-news-card-1
Human Drugs

FDA Will Review Ketamine-Based Drug Without New Trials: NRx

NRx Pharmaceuticals says FDA has indicated it is willing to review a potential NDA for its investigational therapy NRX-100 without requiring additiona...

latest-news-card-1
Human Drugs

NovaBridge Says FDA Open to Accelerated Approval for Givastomig

FDA has told NovaBridge Biosciences that its investigational cancer therapy givastomig could be eligible for an accelerated approval pathway following...

latest-news-card-1
Human Drugs

FDA Accepts Sun Pharma Filing to Expand Ilumya Use

FDA accepts for review a Sun Pharmaceutical Industries supplemental BLA seeking to expand the use of Ilumya (tildrakizumab-asmn) to treat adults with ...

latest-news-card-1
FDA General

FDA Warning Letters Surge in FY2025, Report Finds

A regulatory consulting firm's report finds that FDA sharply increased enforcement activity against drugmakers and distributors in fiscal year 2025, i...

Animal Drugs

Enforcement, Advertising Oversight Shape Regulatory Landscape: Legal Update

A legal update from ArentFox highlight several emerging regulatory and enforcement developments at FDA thatare expected to have significant implicatio...

Biologics

Uncertainty for Gene Therapy, Rare Disease & Vaccines in Prasad Exit Wake

CBER director Vinay Prasads departure at the end of next month raises questions across the biotechnology sector about how the agencys approach to vacc...

latest-news-card-1
Human Drugs

Concerns Mount Over Fast Drug Review Voucher Program

Former FDA official Grail Sipes says questions are emerging about the long-term impact of the Commissioners National Priority Voucher program, warning...